- Home
- MITQ vs PULM Comparison
MITQ vs PULM Comparison
Compare MITQ & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MITQ | PULM |
|---|---|---|
| Founded | N/A | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0M | 5.7M |
| IPO Year | 2019 | 2013 |
Fundamental Metrics
Financial Performance| Metric | MITQ | PULM |
|---|---|---|
| Price | $0.65 | $1.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 64.2K | 26.7K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46.18 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $20,139,000.00 | $7,910,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $58.00 | ★ N/A |
| Revenue Growth | N/A | ★ 5069.93 |
| 52 Week Low | $0.42 | $1.16 |
| 52 Week High | $1.66 | $5.50 |
Technical Indicators
Market Signals| Indicator | MITQ | PULM |
|---|---|---|
| Relative Strength Index (RSI) | 68.06 | 43.93 |
| Support Level | $0.60 | $1.44 |
| Resistance Level | $0.66 | $1.55 |
| Average True Range (ATR) | 0.05 | 0.08 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 59.86 | 28.33 |
Price Performance
Historical ComparisonAbout MITQ Moving iMage Technologies Inc.
Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).